The Spanish Bioindustry Association (ASEBIO), in collaboration with the Navarre Society of Development (SODENA), and the government of Navarre, will host BioSpain 2010 (http://www.biospain.org), the biennial international gathering of experts in the biotechnology sector, in Pamplona from September 29th to October 1st. BioSpain 2010 is honoured to welcome three lecturers of international prestige: Mr. Carlos Cordon-Cardo, Vice-Chair of Pathology & Professor, Columbia University; Mr. Larry Fritz, President & CEO, Covella Pharmaceuticals Inc. and Life Science Venture Partner, Westfield Capital Management Company LP; and Mr. Conny Bogentoft, CEO Karolinska Development AB.
Internationalization will be the highlight of BioSpain this year – over 160 companies have already confirmed their participation in the trade exhibition area, a 33% increase on BioSpain 2008.
BioSpain 2010 will feature an extensive program of breakout sessions addressing the most relevant topics in the current biotech scenario, including:
- Orphan Drugs & Rare Diseases
- Alzheimer's and other neurodegenerative diseases: "What is the
Spanish industry doing to develop new drugs?"
- Protein Production & Biosimilars
- Bioinformatics solutions for genomics: from sequences to
Biotechnology and Biomedicine
- Alternative Equity Market for Growth Companies
- Venture Capital
- Biotech's Next Big Thing?
- Joint Technology Cooperation Projects between Spain and other
countries: Eureka & Canadeka
- International Technology Commercialization: The Challenges of
US-European Public-Private Partnerships.
As on previous occasions, BioSpain 2010 will also host the scientific conference organized by the Spanish Society of Biotechnology (SEBIOT), Biotec 2010.
An international round-table called “Opportunities and Challenges in Global Biomarkets,” has also been confirmed. Its main aim is to discuss the present state of the biotechnological industry, its development, and its future prospects.
One of the most attractive aspects of BioSpain 2010 is the opportunity for networking, with over 1,200 delegates from 650 companies & institutions expected to attend.
Furthermore, the investors’ forum seeks to find new financing sources for future entrepreneurial projects. 30 companies will present their business plan to an audience of experts and investors, including representatives of Merck & Co, Bay City Capital, La Caixa, Ysios Capital Partners, GlaxoSmithKline Pharmaceuticals, Forbion Capital Partners, Suanfarma Biotech, McKinsey & Company, and PharmaVentures.